The treatment of mild hypertension in the elderly, a prospective study using multiple regression analysis
Related Experiment Video
Updated: Sep 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Insights
Drug treatment significantly reduced dropouts in elderly patients with mild hypertension compared to placebo. This benefit was observed in individuals aged 75 and older, but not in those over 85.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Clinical Pharmacology
Background:
- Mild hypertension in the elderly is a significant concern.
- Understanding the impact of treatment on this demographic is crucial for public health.
- Previous studies may not have sufficiently addressed the specific benefits and risks in advanced age groups.
Purpose of the Study:
- To investigate the efficacy of drug treatment versus placebo in managing mild hypertension in aged individuals.
- To determine if age influences the effectiveness or dropout rates in hypertension treatment trials.
- To identify key predictors of dropout in elderly patients undergoing hypertension management.
Main Methods:
- A 4-year prospective trial comparing drug treatment with placebo in elderly patients (average age 76.5 years).
- Patients were matched for blood pressure, sex, and age.
- Dropouts were defined by cardiovascular complications or severe blood pressure elevation (e.g., >200/110 mmHg).
Main Results:
- Drug treatment significantly reduced overall dropout rates (10.5%) compared to placebo (41.5%, p<0.01).
- Diastolic hypertension showed a marked reduction in dropouts with drug treatment (9.5%) versus placebo (63.6%, p<0.001).
- No significant difference in dropouts was observed for systolic hypertension; however, drug treatment benefited patients aged 75+ but not those over 85.
Conclusions:
- Drug treatment is beneficial for mild hypertension in the elderly, particularly those aged 75 and above, by reducing dropout rates.
- Placebo (no treatment) was the strongest predictor of dropout, followed by diastolic hypertension, creatinine levels, and age.
- Further research may be needed to refine treatment strategies for the very elderly (over 85).
Abstract:
In order to examine the effect of treatment of mild hypertension of the aged, a 4 year prospective trial was performed in 41 placebo and 38 drug-treated patients with an average age of 76.5 years. Patients were matched for blood pressure, sex and age. Patients with cardiovascular complications or blood pressure elevation above 200/110 were categorized as dropouts and totaled 17 cases (41.5%) in the placebo group, and 4 cases (10.5%) in the drug-treated group (p less than 0.01). In diastolic hypertension, dropouts formed 63.6% of the placebo group (mean BP, 170/92), and 9.5% of the drug group (mean BP, 179/94) (p less than 0.001). In systolic hypertension, dropouts were of 15.8% in the placebo group (mean BP, 164/79), and of 11.8% in the drug group (mean BP, 167/79), and no significant difference was observed. In the placebo group, dropouts were significantly higher in patients with pretreatment systolic blood pressure over 170 mmHg or diastolic blood pressure over 90 mmHg. In patients of 75 years of age or more, dropouts were 46.4% in the placebo group, and 13.0% in the drug treated group showing the beneficial effect of drug treatment even in those over the age of 75. However, no beneficial effect was observed over the age of 85. Stepwise multiple regression analysis of total case revealed that the greatest predictor for dropout was the presence of placebo (i.e. no treatment), explaining 12.2% of the variation in future dropout. Similarly, diastolic hypertension explained 7.5%, creatinine 6.7%, and age 4.6% of this variation.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Drug Dosing: Geriatric Patients
Hypertension I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
